Bayer Posts €2.8 Billion Profit but Legal Costs Sap €2.3 Billion in Cash Ahead of Crucial Supreme Court Ruling

Bayer swings to €2.8B net profit in Q1 2026, but legal costs drag free cash flow to -€2.3B. Supreme Court ruling on Roundup labels due by July; stock down 10% monthly.

The agricultural and pharmaceutical giant swung back into the black during the first quarter of 2026, reporting a net profit of €2.8 billion on revenue of €13.4 billion. That marks a sharp reversal from the deep losses booked a year earlier, and earnings per share on an adjusted basis climbed to €2.71. Yet beneath the headline numbers, a familiar drain persists: legal settlements and litigation expenses pulled free cash flow to a negative €2.3 billion over the three-month period, highlighting just how much the legacy Roundup and PCB cases continue to weigh on the balance sheet.

Much of the operating momentum came from the Crop Science division, which generated €21.6 billion in full-year 2025 revenue and drove the Q1 uptick. The pharma segment, by contrast, saw earnings slip, and the consumer health unit contributed a more modest €5.8 billion to the top line last year. Management has left its full-year guidance unchanged, targeting sales of up to €46.5 billion and operating earnings of roughly €9.5 billion, but the path to those figures depends heavily on two unknowns: the final bill from glyphosate litigation and the looming patent cliff in the drugs portfolio.

The most immediate overhang is the U.S. Supreme Court. Oral arguments in the Durnell case were heard in late April, and a decision is expected by the end of July 2026. CEO Bill Anderson has warned that a ruling against Bayer could create “regulatory anarchy,” because the company maintains that a state-level verdict should not stand when the federal Environmental Protection Agency has already declined to require the warning labels at issue. For investors, the outcome is binary: a victory would sharply reduce the need for additional multi-billion-euro provisions, while a loss could reopen the floodgates.

The company is not waiting idly. By the end of 2026, net debt is targeted to fall to €32 billion, and a further reduction to under €29 billion is planned for the following year. The strategy assumes that the Supreme Court ruling removes enough legal uncertainty to allow the capital structure to be put on a more stable footing. If the targets are met, Bayer would emerge from the litigation era with significantly more financial flexibility.

The stock itself reflects the tension. Shares traded at €37.11 on Monday, down about 1.6% on the day and roughly 10% lower over the past month. That monthly slide has erased some of the year-to-date gains, which still stand at a solid 64%. Analysts are not giving up: the average price target sits at €48.58, and fair-value models peg the intrinsic worth of the company at €40 a share, a meaningful premium to the current level.

Beyond the courtroom, the operating environment remains challenging. European chemical producers are grappling with energy costs that are roughly three times higher than in the U.S., and Chinese competitors have been steadily expanding their production capacity since 2022. Bayer’s own pharma pipeline faces patent expirations that will pressure margins in the coming years, adding another layer of risk to the investment case.

For now, the market is watching the calendar. The end of July marks the next major inflection point. Whether the Supreme Court ruling clears the clouds or thickens them will likely determine whether the stock can sustain its 64% annual gain or surrender more of that ground.